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Abstract
Rare squamous cell carcinoma (SCC) cases associated with vori-
conazole therapy have been reported, but this risk may not
receive enough consideration from clinicians. We describe four
patients presenting with multiple SCC while receiving prolonged
(two to three years) voriconazole therapy. Three patients had
underwent lung transplantation. SCC were preceded by photo-
sensitization lesions, and predominated in photoexposed area,
particularly the face. Therapy associated surgery, chemotherapy
in one case, and voriconazole discontinuation; replacement by
posaconazole or itraconazole did not trigger other photosensi-
tive lesions. Once voriconazole withdrawn, preneoplastic lesions
regressed. In conclusion, prolonged voriconazole therapy may
enhance the risk of photoinduced SCC in immuncompromised
patients, and skin monitoring is mandatory.
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Prolonged voriconazole therapy is suspected to induce
severe phototoxic reactions, photoaging-like damage and
toxic epidermal necrolysis [1,2]. Recently, three cases of
aggressive cutaneous squamous-cell carcinomas have been
described in patients with prolonged voriconazole therapy
[3,4,5]. We report four patients who presented few months
after voriconazole introduction rapidly growing actinic kera-
toses, preceding the onset of aggressive, multiple squamous-
cell carcinomas. The dramatic regression of preneoplasic
lesions after voriconazole discontinuation suggests that it
acts as a promotion factor of tumor progression.
A 40-year-old man (Fitzpatrick phototype II) underwent
lung transplantation in 2001 because of cystic ﬁbrosis. Immu-
nosuppressive therapy comprised steroids, tacrolimus, and
mycophenolate. Voriconazole therapy was started in Septem-
ber 2002 because of persistent Aspergillus colonization.
Photosensitivity-related skin lesions (erythema after short
sunlight exposures, rapidly followed by multiple lentigines
and ephelides) appeared in May 2003. In 2005, multiple acti-
nic keratoses appeared, and biopsies of rapidly growing skin
tumours of the forehead, lip and scalp revealed squamous
cell carcinoma. The dose of immunosuppressive therapy was
lowered, and the squamous cell carcinomas were treated
surgically. In the following months, new actinic keratoses and
squamous cell carcinomas appeared in the scalp (Fig. 1a) and
the right ear canal; surgical therapy was applied. In the fol-
lowing weeks, right cervical metastatic adenopathy appeared
and was treated by complete lymphadenectomy. Voriconaz-
ole was discontinued and replaced by posaconazole. This led
to almost complete disappearance of photosensitivity and
regression of actinic keratoses. Unfortunately, squamous cell
carcinoma metastasis required radiochemotherapy.
A 41-year-old woman (Fitzpatrick phototype II) under-
went chemotherapy and lobectomy in 1999 for lung carci-
noma. She also received methotrexate from 2000 to 2004
for rheumatoid arthritis. In 2005, voriconazole therapy was
initiated because of aspergilloma of the post-lobectomy
space. In 2006, pigmented lesions and keratoses were noted
in exposed skin regions (face, arms, and back of the hand). In
2007, biopsies of ﬁve suspect lesions of these areas revealed
squamous cell carcinomas (Fig. 1b–d). These lesions were
surgically removed, and voriconazole was discontinued and
replaced by caspofungin, followed by posaconazole. Keratos-
es disappeared entirely in 9 months (Fig. 1e).
A 24-year-old woman (Fitzpatrick phototype II) under-
went lung transplantation in 2002 for cystic ﬁbrosis.
Immunosuppressive therapy comprised steroids, tacrolimus
and mycophenolate. She received prophylactic voriconazole
therapy because of Aspergillus bronchial colonization from
March 2005 to January 2008. At the end of 2005, photosen-
sitivity and lentigines appeared on light-exposed areas, fol-
lowed by actinic keratoses several months later. In October
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2008, a large invasive desmoplastic squamous cell carcinoma
of the scalp and two pre-carcinomatous lesions of the lower
lip were surgically excised. Eight months after voriconazole
discontinuation, pigmented lesions had regressed and 50% of
actinic keratoses had disappeared.
A 53-year-old man (Fitzpatrick phototype IIIa) underwent
lung transplantation in 2002 for emphysema. Immunosup-
pressive therapy consisted of steroids, tacrolimus and myco-
phenolate. He received voriconazole therapy from March
2006 to August 2008 because of Aspergillus lung colonization.
Chronic rejection was diagnosed in July 2006. In 2007,
he developed photosensitivity and pigmented lesions of
light-exposed skin. In May 2008, actinic keratoses of the
arms and face were noted. In August 2008, he presented a
left temporal squamous cell carcinoma, which was treated
surgically. After voriconazole was replaced by itraconazole,
actinic keratoses disappeared in 4 months.
In the last 3 years, we observed in our institution four cases
of voraconazole-associated photosensitivity lesions followed
by multiple squamous cell carcinomas; during the same period,
300 people received voriconazole (including 11 lung transplant
recipients), most of them for <6 months. These observations
support the hypothesis that voriconazole may be associated
with a risk of squamous cell carcinoma in certain patients.
Indeed, as previously described in the literature, our patients
developed photosensitivity and pigmented lesions, followed by
actinic keratoses and squamous cell carcinoma(s) a few
months after voriconazole introduction. All had fair skin, weak
solar exposure, and past or current immunosuppressive
treatment. The patients suffered from a chronic inﬂammatory
lung disease, like one of the previously reported patients [4].
Extracutaneous inﬂammation may have inﬂuenced cutaneous
carcinogenesis. Interestingly, two of our patients and one pre-
viously reported patient developed inﬁltrating large squamous
cell carcinoma of the scalp, which is often well protected from
UV radiation by hair.
Taken together, these cases may typify the patients who
are more at risk of developing malignant lesions during pro-
longed voriconazole therapy—immunocompromised, light-
skinned, and with chronic lung inﬂammation. In such patients,
sun exposure must be drastically reduced, even on the scalp,
and clinical skin monitoring is mandatory.
It is noteworthy that numerous chronically granulopenic
patients, because of haematological malignancy, are receiving
long-term voriconazole therapy in our institution, but no
case of squamous cell carcinoma has been reported in this
population (the prevalence of voriconazole-associated photo-
sensitivity in this population is not known). This may suggest
that immunosuppressive therapy targeting lymphocyte
activation is speciﬁcally involved. More generally, fewer than
ten patients receiving voriconazole have been sent to the
dermatological unit of our institution for photosensitivity
(a) (b)
(d)(c) (e)
FIG. 1. (a) Squamous cell carcinomas of
the scalp in patient 1. (b–d) Squamous cell
carcinomas of the hand and face in
patient . (e) Patient 2 after voriconazole
withdrawal and squamous cell carcinoma
surgery.
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during the same period, but we could not determine this
number more precisely.
To our knowledge, voriconazole is the ﬁrst non-immuno-
suppressive drug to be shown to directly inﬂuence skin carci-
nogenesis. Other studies have shown an elevated risk factor
for other photosensitizing drug classes, such as diuretics [6],
but the link with therapy and squamous cell carcinoma was
not so obvious. The speed of development of preneoplastic
keratoses and of aggressive squamous cell carcinoma(s)
suggests that voriconazole may act as a promoting agent in
such predisposed patients. Regression of preneoplastic lesions
after voriconazole withdrawal supports this hypothesis.
Posaconazole therapy did not trigger skin lesions in patients 1
and 2, nor did itraconazole in patient 4, revealing that the
effect of voriconazole or a voriconazole metabolite is speciﬁc.
The precise mechanisms of both photosensitivity and skin
carcinogenesis are not known. Oxidative stress is known to
be of the ﬁrst importance in UV-induced skin damage, and
generation of reactive oxygen species and/or nitric oxide by
voriconazole or its metabolites may be implicated. It has also
been suggested that voriconazole may inhibit a step in the
metabolism of vitamin A, leading to an indirect retinoid
effect. On the other hand, immunosuppression is a well-
known risk factor for malignancy, and is probably synergisti-
cally involved in the rapid onset of squamous cell carcinoma.
In conclusion, physicians must be aware of possible aggres-
sive squamous cell carcinoma in immunocompromised
patients receiving prolonged voriconazole therapy, and of the
possibility of developing skin phototoxicity (mainly actinic ker-
atoses). Prevention is based on rigorous photoprotection and
cutaneous monitoring. If photosensitivity develops, therapy
must be immediately withdrawn. To our knowledge, vorico-
nazole is the ﬁrst non-immunosuppressive molecule that has
been clearly shown to induce skin carcinoma. Studies on
mechanisms involved in voriconazole-induced carcinogenesis
should provide new data on UV-induced carcinogenesis.
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Abstract
To evaluate compliance with preparedness plans, actors simulat-
ing avian inﬂuenza attended various hospital emergency depart-
ments and public health centres during the last quarter of 2007.
Most centres (89%) did not respond correctly. The useful infor-
mation obtained was sent to the medical and administrative staff
who were responsible for the preparedness plans. Awareness of
these errors and their rectiﬁcation can lead to improvements in
the response to any case of inﬂuenza with pandemic potential
and in the capacity to combat any other emergent or re-emer-
gent community infection.
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